{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:27:45Z","timestamp":1773055665350,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Los Angeles County Department of Public Health (DPH) Substance Abuse Prevention and Control","award":["PH-000179"],"award-info":[{"award-number":["PH-000179"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jsat.2015.12.004","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T03:46:29Z","timestamp":1451360789000},"page":"66-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County"],"prefix":"10.1016","volume":"63","author":[{"given":"Sarah J.","family":"Cousins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ramin","family":"Radfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desir\u00e9e","family":"Cr\u00e8vecoeur-MacPhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Ang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendall","family":"Darfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2015.12.004_bb0005","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1360-0443.2009.02538.x","article-title":"Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users","volume":"104","author":"Banta-Green","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2015.12.004_bb0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.amepre.2011.06.045","article-title":"Economic costs of excessive alcohol consumption in the U.S., 2006","volume":"41","author":"Bouchery","year":"2011","journal-title":"American Journal of Preventive Medicine"},{"issue":"Suppl. 8","key":"10.1016\/j.jsat.2015.12.004_bb0015","first-page":"S222","article-title":"Extended-release naltrexone for alcohol dependence: Persistence and healthcare costs and utilization","volume":"17","author":"Bryson","year":"2011","journal-title":"American Journal of Managed Care"},{"key":"10.1016\/j.jsat.2015.12.004_bb0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/1097-4679(198609)42:5<825::AID-JCLP2270420526>3.0.CO;2-B","article-title":"Retention and outcome in a narcotic antagonist treatment program","volume":"42","author":"Capone","year":"1986","journal-title":"Journal of Clinical Psychology"},{"key":"10.1016\/j.jsat.2015.12.004_bb0025","series-title":"Medication-assisted treatment for opioid addiction in opioid treatment programs","author":"Center for Substance Abuse Treatment (CSAT)","year":"2005"},{"key":"10.1016\/j.jsat.2015.12.004_bb0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.drugalcdep.2009.10.014","article-title":"Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: Secondary analyses from a NIDA Clinical Trials Network study","volume":"107","author":"Chakrabarti","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2015.12.004_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jsat.2015.12.004_bb0040","article-title":"A demonstration project Implementing extended-release naltrexone in Los Angeles County","author":"Cousins","year":"2015","journal-title":"Substance Abuse"},{"key":"10.1016\/j.jsat.2015.12.004_bb0045","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1521-0391.2010.00070.x","article-title":"A randomized trial of oral naltrexone for treating opioid-dependent offenders","volume":"19","author":"Coviello","year":"2010","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.jsat.2015.12.004_bb0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/08897077.2011.609438","article-title":"A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers","volume":"33","author":"Coviello","year":"2012","journal-title":"Substance Abuse"},{"issue":"SARC Suppl. 4","key":"10.1016\/j.jsat.2015.12.004_bb0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/02791072.2007.10399899","article-title":"The rise in treatment admissions for primary methamphetamine use in Los Angeles County from 2001 through 2005","author":"Cr\u00e8vecoeur","year":"2007","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2015.12.004_bb0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsat.2015.03.003","article-title":"Extended-release naltrexone for alcohol and opioid problems in Missouri parolees and probationers","volume":"56","author":"Crits-Christoph","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2015.12.004_bb0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2011.06.023","article-title":"Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trial","volume":"120","author":"DeFulio","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2015.12.004_bb0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","article-title":"Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study","volume":"131","author":"Dreifuss","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2015.12.004_bb0075","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jsat.2007.05.003","article-title":"Predictors of methadone maintenance treatment utilization in a multisite cohort of illicit opioid users (OPICAN)","volume":"34","author":"Fischer","year":"2008","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2015.12.004_bb0080","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1360-0443.2010.03015.x","article-title":"Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: Preliminary case-series and feasibility","volume":"105","author":"Fishman","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2015.12.004_bb0085","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","article-title":"Psychometric properties of the Penn Alcohol Craving Scale","volume":"23","author":"Flannery","year":"1999","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"10.1016\/j.jsat.2015.12.004_bb0090","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0376-8716(83)90042-X","article-title":"Predictors of favorable outcome following naltrexone treatment","volume":"12","author":"Greenstein","year":"1983","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2015.12.004_bb0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.31887\/DCNS.2007.9.2\/hkleber","article-title":"Pharmacologic treatments for opioid dependence: Detoxification and maintenance options","volume":"9","author":"Kleber","year":"2007","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.jsat.2015.12.004_bb0105","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: Long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2015.12.004_bb0110","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2015.12.004_bb0115","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11920-010-0135-5","article-title":"Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available","volume":"12","author":"Krupitsky","year":"2010","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.jsat.2015.12.004_bb0120","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended\u2010release naltrexone: A pilot proof\u2010of\u2010concept randomized effectiveness trial","volume":"110","author":"Lee","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2015.12.004_bb0125","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/10826084.2013.800112","article-title":"Engagement, retention, and abstinence for three types of opioid users in Florida","volume":"48","author":"McCabe","year":"2013","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2015.12.004_bb0130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11606-007-0129-0","article-title":"Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients","volume":"22","author":"Moore","year":"2007","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2015.12.004_bb0135","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/ADM.0000000000000125","article-title":"Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): Who will respond?","volume":"9","author":"Nunes","year":"2015","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2015.12.004_bb0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/alcalc\/agh151","article-title":"Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone?","volume":"40","author":"Rubio","year":"2005","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/j.jsat.2015.12.004_bb0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2013.05.030","article-title":"Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade?","volume":"133","author":"Sullivan","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2015.12.004_bb0150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/10550490500528464","article-title":"Predictors of retention in naltrexone maintenance for opioid dependence: Analysis of a stage I trial","volume":"15","author":"Sullivan","year":"2006","journal-title":"American Journal on Addictions"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547215003141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547215003141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:44:05Z","timestamp":1760039045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547215003141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":29,"alternative-id":["S0740547215003141"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2015.12.004","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2015.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}